The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Wet Age Related Macular Degeneration (AMD) Market Research Report 2025
Synopsis
Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
The global Wet Age Related Macular Degeneration (AMD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.
This report aims to provide a comprehensive presentation of the global market for Wet Age Related Macular Degeneration (AMD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Age Related Macular Degeneration (AMD).
Report Scope
The Wet Age Related Macular Degeneration (AMD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Wet Age Related Macular Degeneration (AMD) market comprehensively. Regional market sizes, concerning products by Type, by Age, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Wet Age Related Macular Degeneration (AMD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Age, and by regions.
Market Segmentation
By Company
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)
Segment by Type
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)
Segment by Age
Above 75 Years
Above 60 Years
Above 40 Years
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Age, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Wet Age Related Macular Degeneration (AMD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Age, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
The global Wet Age Related Macular Degeneration (AMD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.
This report aims to provide a comprehensive presentation of the global market for Wet Age Related Macular Degeneration (AMD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Age Related Macular Degeneration (AMD).
Report Scope
The Wet Age Related Macular Degeneration (AMD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Wet Age Related Macular Degeneration (AMD) market comprehensively. Regional market sizes, concerning products by Type, by Age, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Wet Age Related Macular Degeneration (AMD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Age, and by regions.
Market Segmentation
By Company
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)
Segment by Type
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)
Segment by Age
Above 75 Years
Above 60 Years
Above 40 Years
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Age, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Wet Age Related Macular Degeneration (AMD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Age, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Wet Age Related Macular Degeneration (AMD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Wet Age-Related Macular Degeneration (Wet AMD)
1.2.3 Dry Age-Related Macular Degeneration (Dry AMD)
1.3 Market by Age
1.3.1 Global Wet Age Related Macular Degeneration (AMD) Market Growth by Age: 2019 VS 2023 VS 2030
1.3.2 Above 75 Years
1.3.3 Above 60 Years
1.3.4 Above 40 Years
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Wet Age Related Macular Degeneration (AMD) Market Perspective (2019-2030)
2.2 Wet Age Related Macular Degeneration (AMD) Growth Trends by Region
2.2.1 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Wet Age Related Macular Degeneration (AMD) Historic Market Size by Region (2019-2024)
2.2.3 Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Region (2025-2030)
2.3 Wet Age Related Macular Degeneration (AMD) Market Dynamics
2.3.1 Wet Age Related Macular Degeneration (AMD) Industry Trends
2.3.2 Wet Age Related Macular Degeneration (AMD) Market Drivers
2.3.3 Wet Age Related Macular Degeneration (AMD) Market Challenges
2.3.4 Wet Age Related Macular Degeneration (AMD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Revenue
3.1.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Revenue (2019-2024)
3.1.2 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Players (2019-2024)
3.2 Global Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Wet Age Related Macular Degeneration (AMD) Revenue
3.4 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio
3.4.1 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Wet Age Related Macular Degeneration (AMD) Revenue in 2023
3.5 Wet Age Related Macular Degeneration (AMD) Key Players Head office and Area Served
3.6 Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
3.7 Date of Enter into Wet Age Related Macular Degeneration (AMD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Wet Age Related Macular Degeneration (AMD) Breakdown Data by Type
4.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Type (2019-2024)
4.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Type (2025-2030)
5 Wet Age Related Macular Degeneration (AMD) Breakdown Data by Age
5.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Age (2019-2024)
5.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Age (2025-2030)
6 North America
6.1 North America Wet Age Related Macular Degeneration (AMD) Market Size (2019-2030)
6.2 North America Wet Age Related Macular Degeneration (AMD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2019-2024)
6.4 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size (2019-2030)
7.2 Europe Wet Age Related Macular Degeneration (AMD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2019-2024)
7.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size (2019-2030)
8.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Wet Age Related Macular Degeneration (AMD) Market Size (2019-2030)
9.2 Latin America Wet Age Related Macular Degeneration (AMD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2019-2024)
9.4 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size (2019-2030)
10.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis International (Switzerland)
11.1.1 Novartis International (Switzerland) Company Detail
11.1.2 Novartis International (Switzerland) Business Overview
11.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
11.1.4 Novartis International (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.1.5 Novartis International (Switzerland) Recent Development
11.2 Bayer (Germany)
11.2.1 Bayer (Germany) Company Detail
11.2.2 Bayer (Germany) Business Overview
11.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Introduction
11.2.4 Bayer (Germany) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.2.5 Bayer (Germany) Recent Development
11.3 Acucela (US)
11.3.1 Acucela (US) Company Detail
11.3.2 Acucela (US) Business Overview
11.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.3.4 Acucela (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.3.5 Acucela (US) Recent Development
11.4 Neurotech Pharmaceuticals (US)
11.4.1 Neurotech Pharmaceuticals (US) Company Detail
11.4.2 Neurotech Pharmaceuticals (US) Business Overview
11.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.4.4 Neurotech Pharmaceuticals (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.4.5 Neurotech Pharmaceuticals (US) Recent Development
11.5 Ophthotech (US)
11.5.1 Ophthotech (US) Company Detail
11.5.2 Ophthotech (US) Business Overview
11.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.5.4 Ophthotech (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.5.5 Ophthotech (US) Recent Development
11.6 GlaxoSmithKline (US)
11.6.1 GlaxoSmithKline (US) Company Detail
11.6.2 GlaxoSmithKline (US) Business Overview
11.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.6.4 GlaxoSmithKline (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.6.5 GlaxoSmithKline (US) Recent Development
11.7 Alimera Sciences (US)
11.7.1 Alimera Sciences (US) Company Detail
11.7.2 Alimera Sciences (US) Business Overview
11.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.7.4 Alimera Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.7.5 Alimera Sciences (US) Recent Development
11.8 StemCell (Canada)
11.8.1 StemCell (Canada) Company Detail
11.8.2 StemCell (Canada) Business Overview
11.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Introduction
11.8.4 StemCell (Canada) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.8.5 StemCell (Canada) Recent Development
11.9 F. Hoffmann-La Roche (Switzerland)
11.9.1 F. Hoffmann-La Roche (Switzerland) Company Detail
11.9.2 F. Hoffmann-La Roche (Switzerland) Business Overview
11.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
11.9.4 F. Hoffmann-La Roche (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.9.5 F. Hoffmann-La Roche (Switzerland) Recent Development
11.10 Regeneron Pharmaceutical (US)
11.10.1 Regeneron Pharmaceutical (US) Company Detail
11.10.2 Regeneron Pharmaceutical (US) Business Overview
11.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.10.4 Regeneron Pharmaceutical (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.10.5 Regeneron Pharmaceutical (US) Recent Development
11.11 Allergan (Ireland)
11.11.1 Allergan (Ireland) Company Detail
11.11.2 Allergan (Ireland) Business Overview
11.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Introduction
11.11.4 Allergan (Ireland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.11.5 Allergan (Ireland) Recent Development
11.12 Adverum Biotechnologies (US)
11.12.1 Adverum Biotechnologies (US) Company Detail
11.12.2 Adverum Biotechnologies (US) Business Overview
11.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.12.4 Adverum Biotechnologies (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.12.5 Adverum Biotechnologies (US) Recent Development
11.13 Gilead Sciences (US)
11.13.1 Gilead Sciences (US) Company Detail
11.13.2 Gilead Sciences (US) Business Overview
11.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.13.4 Gilead Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2019-2024)
11.13.5 Gilead Sciences (US) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
